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Objective: To evaluate patients’ perceptions of the benefits 
and problems associated with using the actiGait implanted 
drop-foot stimulator
Method: thirteen participants who had suffered a stroke at 
least 6 months prior to recruitment, had a drop-foot that af-
fected walking and had taken part in a trial in which an acti-
Gait drop-foot stimulator had been implanted, completed a 
postal questionnaire.
Results: users agreed that the actiGait had a positive effect 
on walking; they used it regularly and had little difficulty 
with putting it on and taking it off. reliability was a greater 
problem at 90 days than at the final assessment. Ten of the 13 
responders either agreed or strongly agreed with the state-
ment that the actiGait improved their quality of life at 90 
days and 9 out of 12 at the final assessment: 11 of the 12 
respondents would recommend the actiGait to others.
Discussion and conclusion: From the users’ perspective the 
actiGait improved walking, it was reported to be used regu-
larly and it appeared to be easier to use than a surface system. 
users were equivocal about the reliability of the system at 90 
days, but at the final assessment reliability had improved.
Key words: questionnaire, functional electrical stimulation, 
stroke and walking.
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INTRoDuCTIoN
Three studies have reported patients’ perspectives of the value 
and problems associated with drop-foot stimulators (1–3). The 
most important was the study by Taylor et al. (2), which evaluated 
a surface drop-foot system (oDFS) (used by over 2000 patients, 
mainly in the uK). The primary reason for using the device was 
identified as reducing the effort of walking, and the main problems 
identified with the system were in putting it on and taking it off, 
particularly positioning electrodes, and irritation of the skin caused 
by the electrodes. Some patients also cited the reason for discontinu-
ing using the system as the inconvenience of external components, 
particularly the leads. The problems with surface stimulation can be 
overcome by an implanted system, of which the ActiGait stimulator 
is an example. In a recently published phase II trial of 15 patients 
with established hemiplegia due to stroke (4) the ActiGait system 
was found to be safe and effective in improving walking. In this 
paper we present the results of a questionnaire that examined the 
patients’ perceptions of the benefits and problems of the system.
MeThoD
The ActiGait is a 4-channel implantable drop-foot stimulator in which 
electrodes are embedded in a single cuff placed around the common 
peroneal nerve just above the knee. Independent adjustment of output 
from each channel enables fine control of the inversion and eversion 
components of dorsiflexion. Timing of stimulation is triggered by a 
wireless foot-switch and the user is able to switch the device on and 
off and adjust the level of stimulation via an external control unit. A 
fuller description of the system is given by Burridge et al. (4).
ethical approval was granted for a trial (4) to evaluate the safety and 
efficacy of the ActiGait (VN 2002/56mch). All participants were referred 
by their rehabilitation consultant, gave written informed consent and 
understood that data recorded during the study would remain anony-
mous. Participants were over the age of 18 years: full eligibility criteria 
were reported previously (4). Participants were assessed at baseline, at a 
follow-up assessment 90 days post-implantation (n = 13), and at a final 
assessment (final) 15 months after the first participant was implanted 
(n = 15). Questionnaires were posted to participants immediately after 
each post-implantation assessment, and were completed with no input 
from either the researchers or the clinicians involved with the study.
The questionnaire was based on that used by Taylor et al. (2) in the 
evaluation of the oDFS, translated into Danish and adapted for use with 
an implanted system by removing questions about positioning electrodes 
and inconvenience of external wires. Although the questionnaire has not 
been formally validated it has been used in a number of studies (2, 3). 
The questionnaire comprises 9 items related to walking, 2 to the use of 
ActiGait, 2 to practical issues, 13 to the functionality of the ActiGait 
(including one open question), and 3 to general satisfaction. The phras-
ing of the questions is shown in Table I for use and practical issues, 
and in Table II for functionality. The effect on walking questions were 
phrased “When I use the ActiGait:… my walking is faster”; “…I can 
walk further”; “…walking is less effort”; “…I am less likely to trip and 
fall”; “…it is easier to walk on uneven ground”; “…I feel more confident 
walking”; “…I am more independent”; “…my walking is more like it 
was before I became ill”; and “…I am less likely to need a stick, other 
walking aid or help from another person”. Respondents selected one of: 
“strongly agree”, “agree”, “disagree” and “strongly disagree” to each 
question, coded 4, 3, 2 and 1, with higher values indicating better as-
sessment. Cronbach’s alpha for the 9 questions calculated in Stata 9 was 
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0.951 at 90 days, and 0.741 at the final assessment, indicating excellent 
and reasonable internal consistency, respectively. An effect on walking 
score was constructed as the average of the 9 walking items.
Mean (standard deviation (SD)) and range (min–max) of responses on 
the effect on walking score are reported for the 90-day and final assess-
ments, and a paired t-test was carried out to estimate the change over time 
amongst participants with available data at both time-points. The frequen-
cies of responses are presented for the other questionnaire items. Responses 
from key questions are compared with the corresponding figures reported 
for the oDFS (2) in exact χ2 tests carried out in StatXact 6.
ReSuLTS
Fifteen participants underwent implantation surgery: demo-
graphic details of participants were published earlier (4). Thir-
teen completed questionnaires were received at 90 days and 
12 at the final assessment. All questions were answered with 
the exception of 2 walking and 1 functionality question at the 
final assessment. The mean effect on walking scores were 2.9 
(SD 0.8, range 1.3–4.0) at the 90 day and 3.0 (SD 0.5, range 
2.0–3.8) at the final assessment. Amongst the 10 participants 
with available data, the mean effect on walking score was virtu-
ally the same at the 2 assessments (90 days to final assessment 
change 0.0; 95% confidence interval –0.4 to 0.4; p = 0.946). The 
device was worn regularly and the majority used it for most of 
the day at both the 90 days and the final assessment (Table I). 
Two people needed help putting it on at 90 days and one at the 
final assessment, and only 2 said it took longer than 6 min.
Functionality (Table II) was generally good, 12 participants 
responded that the implant gave no discomfort and one reported 
minimal discomfort at 90 days. Three respondents said they had 
some discomfort from the stimulation at 90 days, but at the final 
assessment none found the sensation of stimulation uncomfortable. 
Similarly, ability to adjust the controls improved. At 90 days, 5 
respondents said they needed to make adjustments every 1 or 2 
hours, but at the final assessment all respondents (n = 10) said they 
adjusted it only when they put the device on. Ability to adjust the 
controls did not seem to be a major problem and improved at the 
final assessment, but at 90 days 2 respondents reported difficulty in 
adjusting the controls: one because “I can only use one hand” and 
the other because “the switch turns on and off if my arm touches the 
control box accidentally, therefore it is difficult to say if it is adjusted 
correctly” (both textual responses translated from Danish). Timing 
of the stimulation was considered correct by most participants, with 
only one reporting that it rarely worked at the correct time.
Ten of the 13 responders to the general satisfaction questions 
at 90 days, and 9 of 12 at the final assessment, either agreed or 
Table I. Frequencies of responses concerning the use of the ActiGait 
and practical issues
Assessment
Normally 
every 
day
3–6 
d/w
1–2 
d/w
< 3 
d/w
< 1
d/w
on average how 
often do you use 
your ActiGait?
90 days (n = 13) 12 1 0 0 0
Final (n = 12) 8 2 1 0 1
Most of  
the day 6–9 h 2–5 h < 2 h
on the days that 
you use your Acti-
Gait how long do 
you wear it?
90 days (n = 13) 8 2 3 0
Final (n = 11) 7 2 1 1
< 3 min 3–6 7–10 > 10
how long in 
minutes does it 
take you or your 
carer to put on  
the ActiGait?
90 days (n = 12) 8 3 0 1
Final (n = 12) 10 0 2 0
Do you need  
help to put the 
ActiGait on?
90 days (n = 13) Yes – 2/13 (15%)
Final (n = 12) Yes – 1/12 (8%)
d: days; w: week.
Table II. Frequencies of responses to questions concerning functionality
Assessment
Strongly 
agree Agree
Dis-
agree
Strongly 
disagree
I prefer to use the 
ActiGait rather than 
a splint 
90 days (n = 13) 8 4 1 0
Final (n = 12) 7 5 0 0
The ActiGait is easy 
to use
90 days (n = 13) 5 6 2 0
Final (n = 12) 2 5 5 0
The ActiGait has 
been reliable
90 days (n = 12) 4 4 2 2
Final (n = 12) 5 6 1 0
Any problems I 
have had have been 
addressed quickly 
and effectively
90 days (n = 12) 6 5 1 0
Final (n = 12) 4 5 2 1
The training I was 
given was appropriate
90 days (n = 13) 4 6 3 0
Final (n = 12) 3 8 1 0
The written instruct-
ions were clear and 
easy to understand
90 days (n = 13) 4 9 0 0
Final (n = 12) 3 9 0 0
None
occ/
min Some Severe
Do you have any dis- 
comfort from the 
implanted electrodes?
90 days (n = 13) 12 1 0 0
Final (n = 12) 11 1 0 0
Does the sensation 
from the stimulation 
cause discomfort?
90 days (n = 13) 6 4 3 0
Final (n = 12) 4 8 0 0
Rarely
Some-
times
Mostly 
/often Always
Does the ActiGait 
work at the correct 
time when walking?
90 days (n = 13) 1 1 6 5
Final (n = 12) 1 0 8 3
Does the ActiGait 
work at nappropriate 
times, e.g. in sitting?
90 days (n = 13) 7 2 3 1
Final (n = 12) 7 2 2 1
When I 
put it on
every 
2h > 1/h
every  
5 min
how often do the 
ActiGait settings 
require adjustment?
90 days (n = 11) 6 2 3 0
Final (n = 10) 10 0 0 0
Very 
easy
Fairly 
easy
Diffi-
cult
Very 
difficult
how easy is it for 
you to adjust the 
settings?
90 days (n = 13) 4 7 2 0
Final (n = 12) 7 4 1 0
occ: occasional; min: minimal.
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strongly agreed that the ActiGait improved their quality of life. 
eleven of the 12 respondents would recommend the ActiGait 
to another person. At 90 days all responders either agreed or 
strongly agreed that the cosmetic appearance was good, but 3 
disagreed at the final assessment.
DISCuSSIoN
The mean effect on walking score of 2.9–3.0, corresponding 
to “I agree” with statements of benefit from the device, sug-
gests that users thought the ActiGait improved their walking, 
and their opinion did not change with time from implantation. 
Devices are most commonly evaluated by objective measures 
of walking (4–7); however, these may not present a complete 
and accurate reflection of the benefit (or problems) of a system 
and subjective evaluation provides useful additional informa-
tion about the effect on quality of life. Some problems with the 
timing of the stimulation occurred during the study and were 
resolved following modifications to the wireless connection 
between the foot-switch and the control unit. one user reported 
that this was still a problem at the final assessment.
The effect of the ActiGait on measured walking speed is similar 
to that reported with surface systems (5, 7). More regular and 
extended use may have resulted from the ease of putting on and 
taking off, convenience, reliability or the comfort of the system. 
The results of our study have enabled us to compare the patients’ 
perspective of the ActiGait and the oDFS. Taylor et al. (2) re-
ported results from a survey of current and past users of the oDFS 
who had been using the device for between 1 and 60 months. The 
comparison is summarized in Table III using only data from the 
continuing users of the oDFS (64% of responders). Ideally these 
results should be confirmed in a randomized trial.
Time taken to put the device on (whether help was given or 
not), was approximately 10 min for the oDFS. By comparison, 
8 ActiGait users at 90 days and 10 at the final assessment said 
they were able to put the device on in less than 3 min and only 
one user said it took longer than 10 min (at 90 days). These 
differences may be due to not having to apply electrodes, par-
ticularly as positioning electrodes was cited by 43% of oDFS 
users as a problem. The initial cost of the ActiGait, including 
implantation is likely to be higher than a surface system, but 
running costs would be reduced. Future trials should include 
a cost-effectiveness component.
In conclusion, from the users’ perspective the ActiGait im-
proved walking, was used regularly and appeared to be easier 
to use than a surface system. users were equivocal about the 
reliability of the system at 90 days, but at the final assessment 
reliability was reported to be good.
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Table III. Comparison of usage and reliability between the Odstock Dropped Foot Stimulator (ODFS) and the ActiGait
oDFS* (Ref 2)
ActiGait
90 days Final
n (%) p† n (%) p†
used the device normally everyday 57/107 (53%) 12/13 (92%) 0.007 8/12 (66%) 0.543
used the device all (oDFS) or most (ActiGait)  
of the day on the days that it was worn
41/107 (38%) 8/13 (62%) 0.038 7/12 (58%) 0.221
Needed help putting the device on 31/78 (40%) of those with stroke 2/13 (15%) 0.123 1/12 (8%) 0.050
The device was unreliable‡ 43/107 (40%) 4/12 (33%) 0.762 1/12 (8%) 0.054
*users who were using the oDFS at the time of the questionnaire: 107 out of 160 (67%) of responders.
†exact 2-sample χ2 test against the proportion reported by Taylor et al. (2).
‡Disagreeing or strongly disagreeing with the statement that the ActiGait was reliable in the present study.
J Rehabil Med 40
